Grufity logo
Grufity logo
RLYB

RLYB - Rallybio Corporation Stock Price, Fair Value and News

$15.84-0.06 (-0.38%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

25/100

RLYB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

25/100

RLYB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RLYB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLYB Price Action

Last 7 days

0.1%

Last 30 days

11.4%

Last 90 days

65.1%

Trailing 12 Months

515.1%

RLYB RSI Chart

RLYB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLYB Valuation

Market Cap

83.8M

Price/Earnings (Trailing)

-10.72

Price/Sales (Trailing)

97.67

EV/EBITDA

-5.69

Price/Free Cashflow

-3.04

RLYB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

RLYB Fundamentals

RLYB Revenue

Revenue (TTM)

858.0K

Rev. Growth (Yr)

0%

Rev. Growth (Qtr)

-4.5%

RLYB Earnings

Earnings (TTM)

-7.8M

Earnings Growth (Yr)

12.3%

Earnings Growth (Qtr)

-41.46%

RLYB Profitability

EBT Margin

-877.62%

Return on Equity

-15.55%

Return on Assets

-14.35%

Free Cashflow Yield

-32.92%

RLYB Investor Care

Shares Dilution (1Y)

1.71%

Diluted EPS (TTM)

-1.37

RLYB Alerts

  • 1 major insider buys recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026858.0K---
2025848.0K761.0K674.0K858.0K
20245.9M4.6M3.3M1.9M
20233.4M4.8M5.8M6.1M
2022134.0K391.0K904.0K2.0M
2021141.8K112.5K83.3K54.0K
2020---171.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Rallybio Corporation

RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
 CEO
 WEBSITErallybio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45

Rallybio Corporation Frequently Asked Questions

RLYB is the stock ticker symbol of Rallybio Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Rallybio Corporation is 84.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, RLYB's PE ratio (Price to Earnings) is -10.76 and Price to Sales (PS) ratio is 98.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLYB PE ratio will change depending on the future growth rate expectations of investors.